pentosaceus strains, but only in two W. cibaria strains, while the three Lc. cremoris strains showed β-glucosidase but lacked N-acetyl-β-glucosaminidase activity. On the other hand, α-galactosidase, β-glucuronidase, α-mannosidase, PD-0332991 cost and α-fucosidase activities were not detected in any of the tested LAB strains. Table 4 Enzymatic activity profiles of the 49 pre-selected LAB a Species Strain Esterase (C4) Esterase lipase (C8) Leucine arylamidase Valine arylamidase Cystine arylamidase Acid phosphatase
Naphthol-AS-BI- phosphohydrolase β-Galactosidase α-Glucosidase β-Glucosidase N-acetyl-β-glucosaminidase Enterococci E. faecium BNM58 0 0 ≥40 10 10 20 10 0 0 0 0 SMA7 20 20 ≥40 30 20 30 10 0 0 0 0 SMA8 0 0 ≥40 ≥40 5 5 5 5 0 20 ≥40 SMF8 5 5 10 5 5 20 10 0 0 30 0 LPP29 10 10 30 5 20 10 10 0 0 0 0 CV1 0 0 ≥40 ≥40 5 10 20 20 0 30 ≥40 CV2 0 0 ≥40 ≥40 10 10 20 0 0 10 ≥40 TPM76 30 10 20 0 0 0 10 10 0 0 0 TPP2 0 0 ≥40 20 10 10 10 5 0 30 0 Non-enterococci
Lb. carnosus SMA17 0 0 ≥40 ≥40 0 30 20 30 0 30 30 B43 0 0 ≥40 ≥40 0 5 5 10 0 0 0 Lb. curvatus BCS35 0 0 ≥40 10 5 10 20 0 0 5 10 L. cremoris SMF110 0 0 ≥40 ≥40 0 20 20 0 0 30 30 SMF161 0 0 20 0 5 ≥40 20 0 0 0 0 SMF166 0 0 ≥40 ≥40 0 20 20 0 0 10 10 Lc. cremoris SMM69 0 0 10 0 0 0 10 ≥40 30 ≥40 0 BCS251 0 0 5 0 0 0 5 20 20 10 0 BCS252 0 0 10 0 0 0 10 30 20 10 Quisinostat molecular weight 0 P. pentosaceus SMF120 0 Adenosine 0 ≥40 ≥40 20 ≥40 ≥40 0 0 20 20 SMF130 0 0 ≥40 ≥40 20 30 ≥40 20 0 ≥40 ≥40 SMM73 0 0 ≥40 30
10 20 30 20 0 30 ≥40 BCS46 0 0 ≥40 ≥40 5 20 30 30 0 ≥40 ≥40 B5 0 0 30 ≥40 10 10 20 10 0 30 ≥40 B11 0 0 ≥40 30 0 5 20 0 0 30 ≥40 B41 0 0 30 ≥40 0 5 20 5 0 20 ≥40 B260 0 0 ≥40 ≥40 10 20 30 0 0 20 30 P63 0 0 ≥40 ≥40 5 20 20 30 0 30 ≥40 P621 0 0 ≥40 ≥40 0 5 30 0 0 30 ≥40 LPM78 0 0 30 30 5 10 20 20 0 30 ≥40 LPM83 0 0 30 30 5 10 20 30 0 10 ≥40 LPP32 0 0 ≥40 ≥40 5 5 20 0 0 30 ≥40 LPV46 0 0 ≥40 ≥40 5 20 30 5 0 30 30 LPV57 0 0 ≥40 ≥40 5 20 30 30 0 ≥40 ≥40 TPP3 0 0 ≥40 ≥40 5 5 5 10 0 0 0 W. Antibiotic susceptibility determined by the broth microdilution test The distribution of MICs of the tested antibiotics is Regorafenib in vivo summarized in Tables 5 and 6.